Market Research Logo

Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016

Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Refractory Acute Myeloid Leukemia – Pipeline Review, H2 2016, provides an overview of the Refractory Acute Myeloid Leukemia (Oncology) pipeline landscape.

The acute myeloid leukemia cells which resist treatment are referred to as refractory acute myeloid leukemia. Signs and symptoms includes pale skin, swollen gums, minor infections, such as perianal sores, loss of appetite and weight loss and aches or discomfort in bones or joints such as knees, hips or shoulders. Predisposing factors include age, history of other blood cancers or disorders, genetic disorder and past chemotherapy or radiation treatments. Treatment options include drugs not already used during past treatment and conditioning therapy followed by transplantation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Refractory Acute Myeloid Leukemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Refractory Acute Myeloid Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Refractory Acute Myeloid Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Refractory Acute Myeloid Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 34, 39, 1, 3, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 6 and 1 molecules, respectively.Refractory Acute Myeloid Leukemia.

Refractory Acute Myeloid Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Refractory Acute Myeloid Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Refractory Acute Myeloid Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Refractory Acute Myeloid Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Refractory Acute Myeloid Leukemia (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Refractory Acute Myeloid Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Refractory Acute Myeloid Leukemia Overview
Therapeutics Development
Refractory Acute Myeloid Leukemia - Therapeutics under Development by Companies
Refractory Acute Myeloid Leukemia - Therapeutics under Investigation by Universities/Institutes
Refractory Acute Myeloid Leukemia - Pipeline Products Glance
Refractory Acute Myeloid Leukemia - Products under Development by Companies
Refractory Acute Myeloid Leukemia - Products under Investigation by Universities/Institutes
Refractory Acute Myeloid Leukemia - Companies Involved in Therapeutics Development
Refractory Acute Myeloid Leukemia - Therapeutics Assessment
Drug Profiles
Refractory Acute Myeloid Leukemia - Dormant Projects
Refractory Acute Myeloid Leukemia - Discontinued Products
Refractory Acute Myeloid Leukemia - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Refractory Acute Myeloid Leukemia, H2 2016
Number of Products under Development for Refractory Acute Myeloid Leukemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by 4SC AG, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by AbbVie Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Actinium Pharmaceuticals Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by ADC Therapeutics Sarl, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Aeglea BioTherapeutics Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Agios Pharmaceuticals Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Aileron Therapeutics Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Amgen Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Arog Pharmaceuticals Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Array BioPharma Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Astellas Pharma Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by AstraZeneca Plc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by BioLineRx Ltd, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by BioSight Ltd, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Boston Biomedical Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Bristol-Myers Squibb Company, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Calithera Biosciences Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Celgene Corp, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by CTI BioPharma Corp, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Eisai Co Ltd, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Eli Lilly and Company, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by EpiZyme Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Exelixis Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Fate Therapeutics Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by FLX Bio, Inc., H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by FORMA Therapeutics Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Fujifilm Corp, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by GlaxoSmithKline Plc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by GlycoMimetics Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Igenica Biotherapeutics Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Incyte Corp, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Io Therapeutics Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by JW Pharmaceutical Corp, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Karyopharm Therapeutics Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by MacroGenics Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Merck & Co Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Merck KGaA, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by NantKwest Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Novartis AG, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Oxford BioTherapeutics Ltd, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Pfizer Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Pharma Mar SA, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Polaris Pharmaceuticals Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Seattle Genetics Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Sunesis Pharmaceuticals Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by TaiGen Biotechnology Co Ltd, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Tolero Pharmaceuticals Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by Tragara Pharmaceuticals Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by VioQuest Pharmaceuticals Inc, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline by ZIOPHARM Oncology Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Refractory Acute Myeloid Leukemia - Dormant Projects, H2 2016
Refractory Acute Myeloid Leukemia - Dormant Projects (Contd..1), H2 2016
Refractory Acute Myeloid Leukemia - Dormant Projects (Contd..2), H2 2016
Refractory Acute Myeloid Leukemia - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Refractory Acute Myeloid Leukemia, H2 2016
Number of Products under Development for Refractory Acute Myeloid Leukemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report